• Je něco špatně v tomto záznamu ?

Oxidized-LDL and Fe3+/ascorbic acid-induced oxidative modifications and phosphatidylserine exposure in human platelets are reduced by melatonin

A. Sener, D. Ozsavci, O. Bingol-Ozakpinar, O. Cevik, G. Yanikkaya-Demirel, T Yardimci

. 2009 ; 55 (2) : 45-52.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07532220

Low-density lipoprotein (LDL) modifications and platelet activation are major risk factors for cardiovascular diseases. When platelets are exposed to oxidative stress, they become activated. Oxidized LDL (ox-LDL) and metal-catalysed oxidation systems such as Fe3+/ascorbic acid increase free radical production. We wanted to verify whether melatonin has a protective effect against oxidative modifications and phosphatidylserine externalization in platelets induced by ox-LDL and Fe3+/ascorbic acid. For in vitro effects of melatonin on platelets, ADPactivated platelets were incubated with ox-LDL or Fe3+/ascorbic acid for 1 h at 37 oC with or without melatonin. Then platelet malondialdehyde, protein carbonyl and glutathione levels were measured. Platelet phosphatidylserine exposure was measured with annexin-V using flow cytometry. Malondialdehyde, protein carbonyl and phosphatidylserine levels of platelets treated with Fe3+/ascorbic acid significantly increased compared to the control group. Glutathione contents of Fe3+/ascorbic acid-treated platelets significantly decreased. Melatonin pre-treatment of Fe3+/ascorbic acid-treated platelets caused a mar ked reduction in malondialdehyde and phosphatidylserine levels and a marked increase in glutathione levels. Melatonin also caused non-significant reduction in protein carbonyl contents of Fe3+/ascorbic acid-treated platelets. Malondialdehyde, protein carbonyl and phosphatidylserine levels of platelets treated with ox-LDL also significantly increased compared to the control group. Platelet glutathione levels non-significantly decreased with ox-LDL. With addition of melatonin, malondialdehyde, protein carbonyl and phosphatidylserine levels of platelets treated with ox-LDL significantly decreased. These data suggest that melatonin may protect platelets from iron overload-induced and ox-LDL-induced oxidative modifications and also from the triggering signals of apoptosis activation, possibly due to its scavenger effect on toxic free radicals.

Bibliografie atd.

Lit.: 60

000      
00000naa 2200000 a 4500
001      
bmc07532220
003      
CZ-PrNML
005      
20111210152311.0
008      
091030s2009 xr e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Sener, A.
245    10
$a Oxidized-LDL and Fe3+/ascorbic acid-induced oxidative modifications and phosphatidylserine exposure in human platelets are reduced by melatonin / $c A. Sener, D. Ozsavci, O. Bingol-Ozakpinar, O. Cevik, G. Yanikkaya-Demirel, T Yardimci
314    __
$a Department of Biochemistry, Faculty of Pharmacy, Marmara University, Istanbul
504    __
$a Lit.: 60
520    9_
$a Low-density lipoprotein (LDL) modifications and platelet activation are major risk factors for cardiovascular diseases. When platelets are exposed to oxidative stress, they become activated. Oxidized LDL (ox-LDL) and metal-catalysed oxidation systems such as Fe3+/ascorbic acid increase free radical production. We wanted to verify whether melatonin has a protective effect against oxidative modifications and phosphatidylserine externalization in platelets induced by ox-LDL and Fe3+/ascorbic acid. For in vitro effects of melatonin on platelets, ADPactivated platelets were incubated with ox-LDL or Fe3+/ascorbic acid for 1 h at 37 oC with or without melatonin. Then platelet malondialdehyde, protein carbonyl and glutathione levels were measured. Platelet phosphatidylserine exposure was measured with annexin-V using flow cytometry. Malondialdehyde, protein carbonyl and phosphatidylserine levels of platelets treated with Fe3+/ascorbic acid significantly increased compared to the control group. Glutathione contents of Fe3+/ascorbic acid-treated platelets significantly decreased. Melatonin pre-treatment of Fe3+/ascorbic acid-treated platelets caused a mar ked reduction in malondialdehyde and phosphatidylserine levels and a marked increase in glutathione levels. Melatonin also caused non-significant reduction in protein carbonyl contents of Fe3+/ascorbic acid-treated platelets. Malondialdehyde, protein carbonyl and phosphatidylserine levels of platelets treated with ox-LDL also significantly increased compared to the control group. Platelet glutathione levels non-significantly decreased with ox-LDL. With addition of melatonin, malondialdehyde, protein carbonyl and phosphatidylserine levels of platelets treated with ox-LDL significantly decreased. These data suggest that melatonin may protect platelets from iron overload-induced and ox-LDL-induced oxidative modifications and also from the triggering signals of apoptosis activation, possibly due to its scavenger effect on toxic free radicals.
650    _2
$a dospělí $7 D000328
650    _2
$a antioxidancia $x farmakologie $x metabolismus $7 D000975
650    _2
$a kyselina askorbová $x farmakologie $7 D001205
650    _2
$a trombocyty $x metabolismus $x účinky léků $7 D001792
650    _2
$a železité sloučeniny $x farmakologie $7 D005290
650    _2
$a glutathion $x metabolismus $7 D005978
650    _2
$a lidé $7 D006801
650    _2
$a peroxidace lipidů $x účinky léků $7 D015227
650    _2
$a lipoproteiny LDL $x farmakologie $7 D008077
650    _2
$a malondialdehyd $x metabolismus $7 D008315
650    _2
$a melatonin $x farmakologie $7 D008550
650    _2
$a oxidace-redukce $x účinky léků $7 D010084
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a fosfatidylseriny $x metabolismus $7 D010718
700    1_
$a Ozsavci, D.
700    1_
$a Bingol-Ozakpinar, O.
700    1_
$a Cevik, O.
700    1_
$a Yanikkaya-Demirel, G.
700    1_
$a Yardimci, T.
773    0_
$w MED00011004 $t Folia biologica $g Roč. 55, č. 2 (2009), s. 45-52 $x 0015-5500
856    41
$u http://fb.cuni.cz/Data/files/folia_biologica/volume_55_2009_2/fb2009A0009.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y 9
990    __
$a 20091030134314 $b ABA008
991    __
$a 20091111102432 $b ABA008
999    __
$a ok $b bmc $g 691081 $s 552972
BAS    __
$a 3
BMC    __
$a 2009 $b 55 $c 2 $d 45-52 $i 0015-5500 $m Folia biologica (Praha) $x MED00011004
LZP    __
$a 2009-51/ipme

Najít záznam

Citační ukazatele

Možnosti archivace